A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
A Pivotal, Randomized Controlled, Open-Label Study of Tumor Treating Fields (TT Fields) in Patients with Recurrent Ovarian Cancer in Whom Platinum Is an Option.
A Randomized Study of Paclitaxel - Carboplatin followed by maintenance Niraparib versus Paclitaxel - Carboplatin - Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Following a Front-Line Complete Cytoreduction Surgery.
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator's choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer.
A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors.
Phase 3 radomized controlled trial evaluating Avutometinib and Defactinib vs Standard of Care Treatment (Investigators choice) in patients with recurrent LGSOC
A Phase 3 Randomized, Active-Controlled, Open-Label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-Line or Third-Line Treatment for Participants with Recurrent or Metastatic Cervical Cancer.
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting).
A PHASE 3, Randomized, placebo-controlled, Double-Blind, multicenter Trial of selinexor in Maintenance therapy After systemic therapy for Patients with P53 Wild-TYPE, Advanced or Recurrent Endometrial carcinoma.
An international, prospective, randomized, multicenter, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL
A Phase III study of Atezolizumab versus Placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with newly diagnosed stage III/stage IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.
Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.
Phase III study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.
Phase II study Carbo + DLP or paclitaxel with or without farletuzumabplatinum resistant relapses with low levels of CA 125.
Closed
Ovarian Cancer
ENGOT-ov26/GEICO 54-O/PRIMA
PI: A. González
A Phase 3 Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy.
Post-authorization observational restrospective multicenter post-authorization study of the combination with trabectedin and doxorubicinaliposomalpegilated (DLP) in recurrent ovarian cancer.
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Closed
Ovarian Cancer
CLINICAL TRIAL CODE: GEICO 1303-ENGOT OV 16- NOVA (ENGOT)
PI: JM. Del Campo
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer.
Closed
Ovarian Cancer
ENGOT-OV-2b/TRINOVA 3/GEICO-1201
PI: JM. Del Campo
TRINOVA - A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
Closed
Ovarian Cancer
MM-121/GEIC 1202
PI: A. González, A. Redondo, JM. Rubio, A. Poveda
Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers.
Closed
Ovarian Cancer
NCIC-OV 21/GEICO-0902
PI: I. Romero, J. Ponce
Phase II-III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus carboplatin plus IV Paclitaxel in patients with epithelial ovarian carcinoma undergoing optimal cytoreductive surgery following neoadjuvant intravenous chemotherapy.
Closed
Ovarian Cancer
GEICO 1001-CATUMAXOMAB
PI: A. Oaknin
Phase II trial to evaluate the efficacy and safety of catumaxomab as a consolidation treatment for patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in second or third clinical complete remission.
Closed
Ovarian Cancer
AUG-OVAR 12/GEIC 1003
PI: JM. Del Campo
Phase III, multicenter, randomized, double-blind study to evaluate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo in combination with carboplatin and paclitaxel in patients with advanced ovarian cancer.
Closed
Ovarian Cancer
GEICO 1002
PI: A. Oaknin
A prospective, multicenter, uncontrolled phase II clinical trial to determine the clinical benefit and toxicity of Pazopanib, a multidrug receptor tyrosine kinase inhibitor (VEGFR -1, -2, -3, PDGFR-α and β and C-Kit), in patients with platinum-resistant advanced ovarian cancer.
Closed
Ovarian Cancer
ICON-6/GEIC 1101
PI: A. González
Gynaecologic Cancer Intergroup multicenter, double-blind controlled clinical trial of Cediranib (AZD 2171), in combination with platinum-based chemotherapy and as a single agent in maintenance therapy, in women with ovarian cancer who have relapsed more than 6 months after completion of first-line platinum-based treatment.
Closed
Ovarian Cancer
AURELIA/GEIC 0904
PI: A. Poveda
AURELIA: Multicenter, open-label, randomized, two-arm, multicenter phase III clinical trial of bevacizumab in combination with chemotherapy versus chemotherapy alone in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Closed
Ovarian Cancer
GEICO 0901/AGO-OVAR 16
PI: JM del Campo
Phase III study to evaluate the efficacy and safety of pazopanib in monotherapy versus placebo among women with epithelial ovarian, fallopian tube or primary peritoneal cancer who have not progressed after first-line chemotherapy.
Closed
Ovarian Cancer
GEICO 0905-OCTAVIA
PI: A. González
A single-arm Phase II clinical study of the combination of carboplatin and weekly periclitar plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer.
Closed
Ovarian Cancer
GEICO 0802/HECTOR-PHASE III-2006
PI: A. González, A. Santaballa
Topotecan plus carboplatin versus standard therapy (paclitaxel plus carboplatin or gemcitabine plus carboplatin) in the treatment of patients with recurrent peritoneal carcinoma, tubal carcinoma or plantin-sensitive epithelial ovarian carcinoma.
Closed
Ovarian Cancer
GEICO 0804-R
PI: B. Ojeda
Bevacizumab database in relapsed ovarian cancer.
Closed
Ovarian Cancer
GEICO 0801-T
PI: A. Poveda
Retrospective study of biomarkers in ovarian epithelial cancer.
Closed
Ovarian Cancer
GEICO 0803-R
PI: A. Oaknin
Feasibility and toxicity of a modified outpatient regimen of intravenous/ intraperitoneal chemotherapy (IV/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study.
Closed
Ovarian Cancer
GEICO 0701/ICON-7
PI: A. Cervantes
A randomized, two-group, multicenter "Gynaecologic Cancer InterGroup" study to add bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer.
Closed
Ovarian Cancer
GEICO 0702-T/TOPO IIA
PI: A. González
Determination of TOPO IIA expression in ovarian carcinoma samples from patients treated with pegylated liposomal liposomal doxorubicin.
Closed
Ovarian Cancer
GEICO 0703/MIMOSA
PI: A. Casado
Randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate maintenance treatment with abagovomab in patients with ovarian epithelial carcinoma after complete response to first-line chemotherapy.
Closed
Ovarian Cancer
GEICO 0104
PI: A. González
Randomized phase II study of the carboplatin-gemcitabine doublet followed by carboplatin-paclitaxel versus carboplatin-paclitaxel in patients with platinum-sensitive recurrence of ovarian carcinoma, primary peritoneal carcinomatosis or tubal carcinoma.
Closed
Ovarian Cancer
GEICO 0101
PI: MA. Izquierdo, A. Cervantes
Phase III clinical trial to evaluate treatment with the combination cisplatin plus topotecan followed by paclitaxel plus carboplatin versus paclitaxel plus carboplatin as first-line treatment in women with newly diagnosed advanced epithelial ovarian cancer.
Closed
Ovarian Cancer
GEICO 0103
PI: B. Ojeda
Phase II study with prolonged infusion Gemcitabine in patients with platinum-resistant advanced epithelial ovarian cancer.
Closed
Ovarian Cancer
GEICO CO22
PI: A. Casado
GEICO validation of CAELYX in patients with epithelial ovarian cancer.
Closed
Ovarian Cancer
GEICO 0199
PI: A. González
Randomized phase II clinical trial (with quality of life assessment) of carboplatin versus the combination of taxol and carboplatin in patients with relapsed platinum-sensitive ovarian cancer.
Closed
Ovarian Cancer
GEICO 0299/EORTC 55981/NSGO
PI: MA. Izquierdo, JM del Campo
Randomized clinical trial of Paclitaxel / Epirubicin / Carboplatin in combination (TEC) vs Paclitaxel / Carboplatin (CT) in the treatment of women with advanced ovarian cancer.
Closed
Cervical Cancer
ENGOT-Cx6/GEICO 73-C
PI: A. González
A Phase 2 Trial of TisotumabVedotin (HuMax®-TF- ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer.
Closed
Cervical Cancer
ENGOT-CX1/GEIC 43-O
PI: MJ Rubio
Phase II study of every 3 weeks treatment with carboplatin (AUC 5) + 175 mg/m2 paclitaxel, with or without concomitant and maintenance nintedanib, in advanced or recurrent cervical carcinoma.
Phase II carbo-paclitaxel-bevacizumab in first-line persistent, recurrent or disseminated cervical carcinoma.
Closed
Cervical Cancer
GOG-0240 / GEICO-0903
PI: A. Oaknin
Randomized Phase III trial of Cisplatin plus Paclitaxel with and without Bevacizumab versus the platinum-free doublet, Topotecan plus Paclitaxel, with and without Bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma.
Closed
Cervical Cancer
GEICO 2005/01
PI: MJ Rubio
Exploratory phase II study to evaluate the efficacy and safety of weekly topotecan in the treatment of persistent or recurrent cervical cancer after failure of first-line treatment with platinum derivatives.
Closed
Endometrial Cancer
ENGOT-EN2/GEIC 47-E
PI: A. Santaballa
A Phase III trial of postoperative chemotherapy or no further treatment for patients with node negative stage I/II intermediate or high-risk endometrial cancer.
A phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.
Yondelis in uterine leiomyosarcoma: retrospective study + biomarkers.
Closed
Endometrial Cancer
GEICO P02868/GEIS 7
IP: Andrés Poveda
Phase IV-II trial of Temozolamide in continuous oral administration scheme in the treatment of gynecologic sarcomas.
Gestión de Cookies
Utilizamos cookies propias y de terceros para el correcto funcionamiento, visualización y uso del sitio web por parte del usuario y para mejorar nuestros servicios recogiendo datos estadísticos sobre la navegación de los usuarios en el sitio web. Puede obtener más información sobre las cookies que utilizamos e incluso rechazarlas consultando nuestra Política de cookies. Pulsando el botón 'Aceptar' presta su consentimiento para el uso de las cookies mencionadas.
Funcional
Always active
El almacenamiento o acceso técnico es estrictamente necesario para el propósito legítimo de permitir el uso de un servicio específico explícitamente solicitado por el abonado o usuario, o con el único propósito de llevar a cabo la transmisión de una comunicación a través de una red de comunicaciones electrónicas.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Estadísticas
El almacenamiento o acceso técnico que es utilizado exclusivamente con fines estadísticos.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
El almacenamiento o acceso técnico es necesario para crear perfiles de usuario para enviar publicidad, o para rastrear al usuario en una web o en varias web con fines de marketing similares.
